Nyxoah Q2 Revenue Jumps 74 Percent

Nyxoah(NASDAQ:NYXH) reported second quarter 2025 earnings on August 18, 2025, highlighting FDA Pre-Market Approval (PMA) for its GENEO system, revenue grew 73.8% year-over-year to €1.3 million, and active steps toward full-scale commercialization in the U.S. The company invested significantly in commercial infrastructure, ending June with €43 million in cash and access to an additional €27.5 million from a term debt facility, while reporting a €19.9 million operating loss, with the increase driven by commercial investments in the U.S. ahead of the post-FDA commercial launch. The call detailed strategic differentiators, reimbursement progress, and timelines for expanding patient eligibility and product labeling, setting the stage for accelerated market penetration.The GENEO system is now the first and only bilateral hypoglossal nerve stimulation (AGNS) therapy approved in the U.S. for obstructive sleep apnea (OSA), positioning the company as a direct competitor to Inspire Medical. Nyxoah immediately launched with a commercial team of 50 professionals, targeting over 350 high-volume U.S. implanting accounts, representing 75%-80% of market revenue.The approval unlocks immediate revenue opportunities in the largest global market, making commercial traction and differentiation versus the incumbent critical to the long-term growth thesis.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool